Mats Jerkeman
31 – 40 of 177
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2022
-
Mark
Patient trajectories after diagnosis of diffuse large B-cell lymphoma—a multistate modelling approach to estimate the chance of lasting remission
(
- Contribution to journal › Article
-
Mark
Tackling Mantle Cell Lymphoma in Europe
(
- Contribution to journal › Article
-
Mark
Ibrutinib plus Bendamustine and Rituximab in Untreated Mantle-Cell Lymphoma
(
- Contribution to journal › Article
-
Mark
The EHA Research Roadmap: Malignant Lymphoid Diseases
(
- Contribution to journal › Article
- 2021
-
Mark
How should we use ibrutinib in patients with mantle cell lymphoma?
(
- Contribution to journal › Debate/Note/Editorial
-
Mark
Detailed Long-Term Follow-Up of Patients Who Relapsed after the Nordic Mantle Cell Lymphoma Trials : MCL2 and MCL3
(
- Contribution to journal › Article
-
Mark
Unmarried or less-educated patients with mantle cell lymphoma are less likely to undergo a transplant, leading to lower survival
(
- Contribution to journal › Article
-
Mark
Detecting deviations from the efficacy and safety results of single-arm trials using real-world data : The case of a CAR-T cell therapy in B-cell lymphoma
2021) In Pharmacoepidemiology and Drug Safety(
- Contribution to journal › Article
-
Mark
Incidence of relapsed/refractory diffuse large B-cell lymphoma (DLBCL) including CNS relapse in a population-based cohort of 4243 patients in Sweden
(
- Contribution to journal › Article
-
Mark
Newly diagnosed and relapsed follicular lymphoma : ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
2021) In Annals of oncology : official journal of the European Society for Medical Oncology 32(3). p.298-308(
- Contribution to journal › Article